Lobar Holoprosencephaly
|
0.500 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
Alobar Holoprosencephaly
|
0.500 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
Semilobar Holoprosencephaly
|
0.500 |
GermlineCausalMutation
|
disease |
ORPHANET |
|
|
|
HOLOPROSENCEPHALY 2 (disorder)
|
0.920 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Schizencephaly
|
0.610 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
HOLOPROSENCEPHALY 4 (disorder)
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
HOLOPROSENCEPHALY 3
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
HOLOPROSENCEPHALY 2 (disorder)
|
0.920 |
AlteredExpression
|
disease |
BEFREE |
However, embryonic SIX3 expression is not limited to the eye field, and SIX3 has been found to be mutated in some patients with holoprosencephaly type 2 (HPE2), suggesting that SIX3 has wide implications in head development.
|
10512683 |
1999 |
Carcinogenesis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Importantly, interactions between AURKA and AURKB stabilize and protect AURKA/B from degradation, and overexpression of SIX3 does not affect these interactions; SIX3 also acts as a tumor suppressor, and it increases p53 activity and expression at the post-translational level by the negative regulation of AURKA or AURKB, reduces the events of numerical centrosomal aberrations and misaligned chromosomes, and significantly inhibits the proliferation, invasion, and tumorigenesis of astrocytoma in vitro and in vivo.
|
28595628 |
2017 |
Malignant neoplasm of breast
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, high SIX3 mRNA level was a protective factor for OS and RFS of basal-like breast cancer patients.Our study suggested that members of SIX family played distinct roles in breast cancer.
|
27399099 |
2016 |
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Considering the highly specific expression pattern of Six3, our finding that it is expressed in EMC suggests that it plays a pivotal role in the development of these tumors.
|
12543801 |
2003 |
Breast Carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
However, high SIX3 mRNA level was a protective factor for OS and RFS of basal-like breast cancer patients.Our study suggested that members of SIX family played distinct roles in breast cancer.
|
27399099 |
2016 |
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Epigenetically controlled Six3 expression regulates glioblastoma cell proliferation and invasion alongside modulating the activation levels of WNT pathway members.
|
28643150 |
2017 |
Tumor Cell Invasion
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Upregulation of sine oculis homeobox homolog 3 is associated with proliferation, invasion, migration, as well as poor prognosis of esophageal cancer.
|
30672777 |
2019 |
Extraskeletal Myxoid Chondrosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Considering the highly specific expression pattern of Six3, our finding that it is expressed in EMC suggests that it plays a pivotal role in the development of these tumors.
|
12543801 |
2003 |
Extraskeletal Myxoid Chondrosarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Our data suggest that aberrant coexpression of NOR1 and SIX3 is a potential alternative mechanism underlying the development of EMC.
|
15262426 |
2004 |
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Moreover, SIX3 mRNA expression was associated with significantly improved overall survival (OS) and progression-free survival (PFS) in adenocarcinoma patients and patients with bronchioloalveolar carcinoma (BAC) features.
|
23977152 |
2013 |
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Importantly, interactions between AURKA and AURKB stabilize and protect AURKA/B from degradation, and overexpression of SIX3 does not affect these interactions; SIX3 also acts as a tumor suppressor, and it increases p53 activity and expression at the post-translational level by the negative regulation of AURKA or AURKB, reduces the events of numerical centrosomal aberrations and misaligned chromosomes, and significantly inhibits the proliferation, invasion, and tumorigenesis of astrocytoma in vitro and in vivo.
|
28595628 |
2017 |
Bronchioloalveolar Adenocarcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, SIX3 mRNA expression was associated with significantly improved overall survival (OS) and progression-free survival (PFS) in adenocarcinoma patients and patients with bronchioloalveolar carcinoma (BAC) features.
|
23977152 |
2013 |
Esophageal Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The Kaplan-Meier method and Cox's proportional hazards model were performed to analyze the correlations between SIX3 expression and EC clinical outcomes.
|
30672777 |
2019 |
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Epigenetically controlled Six3 expression regulates glioblastoma cell proliferation and invasion alongside modulating the activation levels of WNT pathway members.
|
28643150 |
2017 |
Glioma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Our results showed that Six3 was down-regulated in human glioma tissues and human glioma SHG-44, U251, SF126 and U373-MG cells compared with the normal tissues.
|
28643150 |
2017 |
Hyperglycemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of SIX2 and SIX3, transcription factors without prior known functions in the pancreas and linked to fasting hyperglycemia risk, increased with age specifically in human islet β cells.
|
27133132 |
2016 |
Osteosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Collectively, two miRNAs, hsa-miR-19-3p and hsa-miR106b-3p, and transcription factor SIX3 were identified and may be reliable markers for prognostic and treatment of osteosarcoma.
|
27315542 |
2017 |
Adenocarcinoma of lung (disorder)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Association of SIX3 expression levels with clinical outcomes of patients with lung adenocarcinoma was evaluated using the Kaplan-Meier method and a multivariate Cox proportional hazards regression model.
|
23977152 |
2013 |